What Illumina's Quarter ended Sep 27, 2026 10-Q says: 3 signals
Illumina filed its latest 10-Q with the SEC on Oct 30, 2026. It discusses debt refinancing, general counsel change and software implementation.
Public (ILMN)Biotechnology Research10,000+ employeesillumina.comLinkedIn
Get Illumina's live signals in Claude or ChatGPT, or by API
What changed at Illumina this week? Use Autobound signals for illumina.com.- Filed
- Oct 30, 2026
- Period
- Quarter ended Sep 27, 2026
- Filings
- 3
- Signals
- 8
Source: Autobound Signal API · 107 signals tracked for Illumina · updated
10-Q · latest 8
What Illumina's 10-Q filings say
- SEC EDGAR
10-Q · Quarter ended Sep 27, 2026
Filed · 3 signals
Illumina issued $300 million of 2029 Term Notes and entered a $1 billion credit facility
In August 2026, Illumina issued $300 million aggregate principal amount of 4.950% notes maturing in 2029 and established a new $1 billion five-year unsecured revolving credit facility.
$300M
aggregate principal amount of 2029 Term Notes issued
4.95%
interest rate per annum on the 2029 Term Notes
Former Chief Legal Officer Scott Davies departed company in August 2026
Scott Davies terminated his Rule 10b5-1 trading arrangement on August 14, 2026, in connection with his departure as Chief Legal Officer.
Illumina implementing global ERP system upgrade targeted to become operational in first half 2027
In Q3 2025, Illumina began implementation efforts for an upgrade of its global enterprise resource planning system to enhance financial data flow, analysis, and reporting, with go-live planned for H1 2027.
enterprise resource planningERP
- SEC EDGAR
10-Q · Quarter ended Jun 28, 2026
Filed · 3 signals
Acquired proteomics provider SomaLogic from Standard BioTools for $460 million total purchase price
Illumina closed the acquisition of SomaLogic on January 30, 2026, for $460 million, consisting of $382 million cash and estimated contingent consideration.
$460M
total purchase price to acquire SomaLogic
high-throughput protein measurement technologydata analysis servicesSOMAmer-based NGS library preparation kits
Illumina Upgrades Global Enterprise Resource Planning System Targeting Go-Live in First Half 2027
Illumina began implementation efforts in Q3 2025 to upgrade its global ERP system to enhance financial data flow, analysis, and reporting, with operational go-live expected in the first half of 2027.
enterprise resource planningERP
Capital expenditures reached $78 million in YTD 2026 driven by facilities investments
Illumina invested $78 million in net purchases of property and equipment in YTD 2026, up from $62 million in YTD 2025, primarily associated with investments in facilities.
$78M
capital expenditures, primarily associated with investments in facilities
- SEC EDGAR
10-Q · Quarter ended Mar 29, 2026
Filed · 2 signals
Completed acquisition of SomaLogic from Standard BioTools for $460 million total purchase price
Illumina acquired proteomics company SomaLogic on January 30, 2026, for $382 million cash and $81 million in estimated contingent consideration.
$460M
total purchase price for SomaLogic acquisition
high-throughput protein measurement technologySOMAmer-based NGS library preparation kits
Global ERP System Upgrade Underway with Operational Launch Planned for First Half of 2027
Illumina began implementation efforts in Q3 2025 to upgrade its global enterprise resource planning (ERP) system, targeting operational go-live in the first half of 2027 to enhance financial information flow and data analysis.
ERPenterprise resource planning
Earnings calls
Illumina earnings headlines
From earnings call transcripts (Signal API type earnings-transcripts).
| Call date | What the company said |
|---|---|
| Q3 revenue $1.17B up 4.7% rest of world organicIllumina reported Q3 2026 revenue of $1.17 billion, reflecting a 4.7% YoY organic growth in Rest of World markets (5% organic overall), driven by NovaSeq X adoption. Sequencing consumables reached $792M (+5% organic RoW), while non-GAAP operating margin expanded 100 bps above guidance to 25.0% and diluted EPS grew 7% to $1.44. | |
| FY2026 revenue guidance raised by $30M to $4.65BFull-year 2026 revenue guidance was increased by $30 million at the midpoint to a range of $4.64 billion to $4.66 billion, backed by Q3 outperformance and expanding NovaSeq X consumables demand. Operating margin targets were raised to approximately 23.6% and diluted EPS guidance was increased to $5.40-$5.45 (+12% to 13% YoY growth). | |
| Partnership with GSK expands consortium for Billion Cell AtlasGSK joined Illumina's consortium to leverage functional single-cell genomics data for target validation and drug discovery. The initiative is expanding from 1 billion to 5 billion cells, creating revenue opportunities in multi-omics and AI training datasets. | |
| Commercializing BioInsight platform uniting AI models and multi-omicsIllumina launched BioInsight ecosystem and software platform bringing together multi-omics assays, curated data, and AI models such as SpliceAI2. The offering aims to drive 1% to 2% incremental top-line growth starting in 2027. | |
| Managing Unreliable Entity List scrutiny and trade restrictionsIllumina is actively navigating regulatory hurdles in China, including the Unreliable Entity List and emerging US export restrictions on Chinese competitors. Despite returning to organic growth in the region in Q3, geopolitical and regulatory overhang persists. | |
| Electronic component pricing and shipping costs driving headwindsManagement cited significant cost inflation from electronic components, shipping freight, and tariffs during 2026. Despite these headwinds, disciplined investment and operational execution enabled operating margins to expand by 400 basis points over 2024 levels. |
Signal API · MCP
Track Illumina with the Signal API
One POST /v1/companies/enrich call with illumina.com returns Illumina 10-Q signals (sec-10q), each with its source. Or ask Claude through MCP.
2 credits per signal returned; zero-result calls are free. Endpoint reference
curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"illumina.com","signal_types":["sec-10q"],"limit":20}'Bulk data
Need this signal for 10,000+ companies?
Get a free sample file or a bulk feed (API, GCS push, flat file). The sample is real 10-Q Filings records, as a CSV.
Same industry
10-Q at related companies
Questions about Illumina 10-Q
When did Illumina file its latest 10-Q?
What did Illumina disclose in its latest 10-Q?
What did Illumina say on its recent earnings calls?
Where can I read Illumina's 10-Q filing?
Page updated , the date of the newest row on this page.
Source. Quarterly reports (Form 10-Q) filed with the SEC. Every card links to the filing on EDGAR.
Method. Insights are extracted from the filing text and grouped by category. Numbers are quoted from the filing.
Data as of .